MLeads Free Trial Offer to Members

Turning leads into sales is complicated, leads are difficult to capture and organize, follow-ups are difficult and sales cycles are long and Team is difficult to manage. 

Track Leads, Manage Customer Relationships and Organize your sales Team in one Place, MLeads

MLeads is built to solve these problems by offering intuitive design and a process that is easy to understand and follow for sales and marketing professionals. MLeads is guaranteed to increase revenue, shorten sales cycles, and streamline processes by offering powerful features like:

  • Lead Retrieval
  • Lead Research
  • Track Leads by Event or Group
  • Lead Follow-ups
  • Measure statistics and ROI
  • Team management

MLeads guarantees to bring efficiency and productivity for any size business anywhere anytime on any devices.

Click the link to claim your free account today!

IF you want more information Please click the link to schedule the demo and one of our support team members will give you the demo.

Download App now: iTunes | Google Play store

Acumen Analytics Announces Creation of Strategic Advisory Board

Leaders in Healthcare and Pharmaceutical Industries to Help Company Maximize Success

Philadelphia, PA, January 29, 2019: Kathleen Brunner, Founder & CEO of Acumen Analytics is delighted to announce the current members of the company’s advisory board. The board is comprised of successful leaders in the healthcare and pharmaceutical industries with decades of experience and knowledge. This team of industry experts will provide informed guidance and strategic advice to the company’s leadership team.

Click here to read full press release

Integrating Clinical and Mental Health

Contributed by NeuroFlow

A recent report from the Bipartisan Policy Center examined the barriers to the integration of clinical health care and mental health services, and identified policy options for consideration in advancing integration of services. Potential opportunities for advancing integrated care include early intervention, grant and demonstration programs, and addressing insurance coverage and payment barriers.

Read more.

Talee Bio Announces $4.5 million Award from the Cystic Fibrosis Foundation to Advance Development of Two Gene Therapy Product Candidates

January 23, 2019, Philadelphia, PA – Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and particularly those individuals with no viable treatment options for the underlying cause of the disease.

TL-101 is an aerosolized, recombinant AAV product candidate to treat pulmonary manifestations of cystic fibrosis of through single or multiple doses. TL-101 is currently in preclinical development with a goal of initiating clinical trials in 2020. TL-102 is an aerosolized lentiviral product candidate with the potential to cure pulmonary manifestations of cystic fibrosis after one dose. Each of these product candidates is the result of decades of research by world-class academic experts developing innovations that overcome historical hurdles to achieving meaningful efficacy in diseased lung.

“We are delighted that the Cystic Fibrosis Foundation is continuing to support the development of these gene therapy product candidates,” commented Joan Lau, CEO of Talee Bio.  She continued, “Gene therapy treatments offer great potential to treat all patients with CF, including those with nonsense mutations and no available treatment options. We are honored to be working with the CF Foundation to expedite the development of these important development products in order to improve and extend the lives of every CF patient.”

About Cystic Fibrosis

Cystic Fibrosis (CF) is a progressive, life-threatening genetic disorder affecting the lungs and digestive system that impacts more than 75,000 worldwide. CF is characterized by thickened mucus and inflammation, especially in the airways, leading to chronic infections and progressively worsening ability to breathe. CF is caused by mutations in the CFTR gene, an ion channel whose malfunction causes the thickening of mucus. Currently, the disease has no cure and leads to premature death at an average age of 39 years.

About Talee Bio

Talee Bio is a development stage biopharmaceutical company focused on developing gene therapy products for the treatment of cystic fibrosis. The company is developing two inhaled gene therapy drug candidates to treat all cystic fibrosis patients: TL-101, a recombinant AAV-based gene therapy, and TL-102, a lentivirus gene therapy. The company was founded by world-class academic researchers from the University of Iowa and the Children’s Hospital of Philadelphia and Militia Hill Ventures, an active-build venture capital firm based in Philadelphia, with support from Emily’s Entourage.

Contact: Joan Lau, PhD | CEO, Talee Bio, Inc. | [email protected]

Intact Vascular Announces Launch of the Tack Endovascular System® in the EU and First Commercial Use in Germany

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System® in multiple hospitals within Germany. A novel therapy for dissection repair following balloon angioplasty, the Tack® implant is a first-of-its kind device for patients with peripheral arterial disease (PAD) and/or critical limb ischemia (CLI).

“The Tack System provides a much needed therapeutic option for treating dissections in the superficial femoral or popliteal arteries following balloon angioplasty,” said Dr. Christian Wissgott, Assistant Director, at Westküstenklinikum Heide in Heide, Germany. “I am very pleased with my experience using the implant and I am excited to incorporate this technology into my above and below the knee treatment algorithms going forward.”

Read more.

Intact Vascular Announces Enrollment Completion of TOBA II BTK Clinical Trial

First-of-its-kind study designed to demonstrate safety and efficacy of the Tack Endovascular System® in treating post-PTA dissections below the knee

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced its Tack Optimized Balloon Angioplasty II BTK (TOBA II BTK) clinical trial successfully completed enrollment, ahead of schedule. This study further augments Intact Vascular’s robust clinical program and is notably the first pivotal trial investigating a permanent vascular implant in arteries below the knee.

“Patients with critical limb ischemia (CLI) experience painful symptoms and are at increased risk of amputation. Unfortunately, therapeutic options are very limited, and no scaffolding solutions are currently FDA-approved for BTK interventions,” commented George Adams, M.D., M.H.S., Director of Cardiovascular and Peripheral Vascular Research, UNC Rex Hospital, Raleigh, North Carolina, Co-Principal Investigator for the TOBA II BTK study. “The potential to have a treatment option that maintains vessel integrity and improves blood flow will have a significant clinical impact for treating patients with below-the-knee disease.”

Read more.